Roche’s cancer and inflammatory diseases drug, MabThera (rituximab), finally faces biosimilar competition in Europe, four years after its patent expired. The Swiss pharma has enjoyed several ...

Roche’s Mabthera (rituximab) blood cancer and inflammatory diseases drug faces cheaper competition for the first time in Europe after regulators approved a near-copy, or biosimilar, from Celltrion.